Micafungine Reig Jofre (Micafungin)

Micafungin blocks the fungal enzyme β‑(1,3)‑D‑glucan synthase, preventing the synthesis of β‑(1,3)‑D‑glucan, an essential structural polysaccharide of the fungal cell wall. This disruption weakens the wall, causing osmotic instability and cell death while sparing human cells.

The specific dose and infusion rate of Micafungine Reig Jofre are determined by the prescribing clinician based on the indication, patient weight, renal and hepatic function, and other clinical factors. Dosage regimens are not standardized in public literature.

Safety data for micafungin in pregnancy and lactation are limited. The product should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and required import documentation.

Micafungin belongs to the echinocandin class, which targets the fungal cell wall, unlike azoles that inhibit ergosterol synthesis or polyenes that bind membrane sterols. Echinocandins generally have a favorable safety profile, limited drug‑drug interactions, and are effective against many Candida species, including those resistant to azoles.

The product must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Prior to use, inspect the solution for particulate matter or discoloration and handle using aseptic technique to maintain sterility.

Micafungine Reig Jofre is given as an intravenous infusion. The infusion is administered by a qualified healthcare professional, typically over a period of 30‑60 minutes, depending on the prescribed dose and patient tolerance.

Serious adverse events include severe hypersensitivity reactions such as anaphylaxis, marked hepatic dysfunction (elevated transaminases or jaundice), acute renal impairment, and severe infusion‑related reactions like hypotension or bronchospasm. Immediate medical attention is required if any of these occur.

Patients with a known hypersensitivity to micafungin or any component of the formulation should avoid the product. Caution is also advised in individuals with severe hepatic or renal impairment, and in those receiving interacting medications listed under major interactions.